Free Trial

Teva Pharmaceutical Industries (TEVA) Competitors

Teva Pharmaceutical Industries logo
$15.51 -0.07 (-0.45%)
As of 03:59 PM Eastern

TEVA vs. TAK, ARGX, BNTX, ONC, SMMT, ITCI, GMAB, RDY, ASND, and MRNA

Should you be buying Teva Pharmaceutical Industries stock or one of its competitors? The main competitors of Teva Pharmaceutical Industries include Takeda Pharmaceutical (TAK), argenx (ARGX), BioNTech (BNTX), Beigene (ONC), Summit Therapeutics (SMMT), Intra-Cellular Therapies (ITCI), Genmab A/S (GMAB), Dr. Reddy's Laboratories (RDY), Ascendis Pharma A/S (ASND), and Moderna (MRNA). These companies are all part of the "pharmaceutical products" industry.

Teva Pharmaceutical Industries vs.

Takeda Pharmaceutical (NYSE:TAK) and Teva Pharmaceutical Industries (NYSE:TEVA) are both large-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, valuation, community ranking, profitability, analyst recommendations, risk, dividends and earnings.

Teva Pharmaceutical Industries has a consensus price target of $23.43, suggesting a potential upside of 51.05%. Given Teva Pharmaceutical Industries' higher probable upside, analysts clearly believe Teva Pharmaceutical Industries is more favorable than Takeda Pharmaceutical.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Takeda Pharmaceutical
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
Teva Pharmaceutical Industries
0 Sell rating(s)
1 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.86

In the previous week, Teva Pharmaceutical Industries had 10 more articles in the media than Takeda Pharmaceutical. MarketBeat recorded 18 mentions for Teva Pharmaceutical Industries and 8 mentions for Takeda Pharmaceutical. Teva Pharmaceutical Industries' average media sentiment score of 1.23 beat Takeda Pharmaceutical's score of 0.86 indicating that Teva Pharmaceutical Industries is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Takeda Pharmaceutical
6 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Teva Pharmaceutical Industries
14 Very Positive mention(s)
2 Positive mention(s)
0 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive

9.2% of Takeda Pharmaceutical shares are held by institutional investors. Comparatively, 54.0% of Teva Pharmaceutical Industries shares are held by institutional investors. 0.0% of Takeda Pharmaceutical shares are held by company insiders. Comparatively, 0.6% of Teva Pharmaceutical Industries shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Teva Pharmaceutical Industries received 1234 more outperform votes than Takeda Pharmaceutical when rated by MarketBeat users. Likewise, 67.84% of users gave Teva Pharmaceutical Industries an outperform vote while only 57.06% of users gave Takeda Pharmaceutical an outperform vote.

CompanyUnderperformOutperform
Takeda PharmaceuticalOutperform Votes
101
57.06%
Underperform Votes
76
42.94%
Teva Pharmaceutical IndustriesOutperform Votes
1335
67.84%
Underperform Votes
633
32.16%

Takeda Pharmaceutical has higher revenue and earnings than Teva Pharmaceutical Industries. Teva Pharmaceutical Industries is trading at a lower price-to-earnings ratio than Takeda Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Takeda Pharmaceutical$4.58T0.01$994.06M$0.4038.20
Teva Pharmaceutical Industries$16.54B1.06-$1.64B-$1.45-10.70

Takeda Pharmaceutical pays an annual dividend of $0.53 per share and has a dividend yield of 3.5%. Teva Pharmaceutical Industries pays an annual dividend of $1.0110 per share and has a dividend yield of 6.5%. Takeda Pharmaceutical pays out 132.5% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Teva Pharmaceutical Industries pays out -69.7% of its earnings in the form of a dividend. Teva Pharmaceutical Industries is clearly the better dividend stock, given its higher yield and lower payout ratio.

Takeda Pharmaceutical has a beta of 0.39, indicating that its stock price is 61% less volatile than the S&P 500. Comparatively, Teva Pharmaceutical Industries has a beta of 0.72, indicating that its stock price is 28% less volatile than the S&P 500.

Takeda Pharmaceutical has a net margin of 4.53% compared to Teva Pharmaceutical Industries' net margin of -9.91%. Teva Pharmaceutical Industries' return on equity of 42.46% beat Takeda Pharmaceutical's return on equity.

Company Net Margins Return on Equity Return on Assets
Takeda Pharmaceutical4.53% 9.39% 4.53%
Teva Pharmaceutical Industries -9.91%42.46%6.65%

Summary

Teva Pharmaceutical Industries beats Takeda Pharmaceutical on 14 of the 20 factors compared between the two stocks.

Get Teva Pharmaceutical Industries News Delivered to You Automatically

Sign up to receive the latest news and ratings for TEVA and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

TEVA vs. The Competition

MetricTeva Pharmaceutical IndustriesPharmaceutical IndustryMedical SectorNYSE Exchange
Market Cap$17.59B$6.85B$5.54B$18.82B
Dividend YieldN/A3.06%5.11%4.03%
P/E Ratio-10.707.4222.3932.47
Price / Sales1.06242.31394.5327.84
Price / Cash5.0565.8538.1817.53
Price / Book3.276.506.764.45
Net Income-$1.64B$143.21M$3.22B$1.02B
7 Day Performance8.46%3.80%2.99%1.77%
1 Month Performance3.02%0.24%-0.22%-3.32%
1 Year Performance10.55%2.51%17.90%4.97%

Teva Pharmaceutical Industries Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
TEVA
Teva Pharmaceutical Industries
3.2557 of 5 stars
$15.51
-0.4%
$23.43
+51.1%
+10.5%$17.59B$16.54B-10.7036,800Upcoming Earnings
Analyst Revision
Positive News
TAK
Takeda Pharmaceutical
2.9033 of 5 stars
$14.85
+1.0%
N/A+16.0%$47.25B$4.58T37.1347,300News Coverage
ARGX
argenx
2.5145 of 5 stars
$596.75
+0.1%
$699.28
+17.2%
+67.7%$36.26B$2.19B-678.13650Positive News
BNTX
BioNTech
2.379 of 5 stars
$101.55
+2.8%
$143.44
+41.2%
+18.2%$24.37B$2.75B-48.363,080Upcoming Earnings
ONC
Beigene
2.341 of 5 stars
$229.83
-0.5%
$316.71
+37.8%
N/A$22.72B$3.81B-27.899,000Analyst Forecast
Analyst Revision
Gap Up
SMMT
Summit Therapeutics
2.6628 of 5 stars
$25.07
+1.9%
$35.40
+41.2%
+508.8%$18.49B$700,000.00-89.53110Upcoming Earnings
Analyst Forecast
Gap Down
ITCI
Intra-Cellular Therapies
0.8805 of 5 stars
$131.87
flat
$109.70
-16.8%
N/A$14.05B$680.50M-151.57560Upcoming Earnings
Analyst Forecast
GMAB
Genmab A/S
4.445 of 5 stars
$20.16
+0.6%
$39.17
+94.3%
-27.2%$13.34B$21.53B11.591,660Analyst Revision
RDY
Dr. Reddy's Laboratories
1.8477 of 5 stars
$13.66
-0.1%
$17.00
+24.5%
-6.4%$11.40B$311.31B21.7524,800Upcoming Earnings
ASND
Ascendis Pharma A/S
2.3354 of 5 stars
$159.98
-3.1%
$204.67
+27.9%
+18.9%$9.75B$363.64M-22.53640Upcoming Earnings
Positive News
MRNA
Moderna
4.3324 of 5 stars
$25.07
+1.4%
$58.70
+134.1%
-75.1%$9.69B$3.20B-2.703,900Upcoming Earnings
Gap Down

Related Companies and Tools


This page (NYSE:TEVA) was last updated on 4/30/2025 by MarketBeat.com Staff
From Our Partners